Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Completed
- Conditions
- Ovarian Carcinoma
- Registration Number
- NCT02297958
- Lead Sponsor
- Rennes University Hospital
- Brief Summary
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 28
Inclusion Criteria
- Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT)
Inclusion Criteria:
- Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.
- Neo adjuvant chemotherapy
Exclusion Criteria
- no neo-adjuvant chemotherapy
- no ovarian carcinoma at final pathological analysis
- less than 18 years old.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response surgery Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery.
- Secondary Outcome Measures
Name Time Method Disease Free Survival rate 18 months after surgery Identification of tumoral T cells surgery Identification of tumoral T cells with FACS analysis of dissociated tumor. Different T cells will be studies: Treg/Th17/Th1/Th2 using antibodies against: CD45/CD3/CD4/CD25/FOXP3 (Treg), CD45/CD3/CD4/IL17A (Th17), CD45/CD3/CD4/CD8/IL4/INF (TCD8 and LTCD4 Th1 et Th2).
Overall survival rate 18 months after surgery
Trial Locations
- Locations (1)
Service de Gynécologie
🇫🇷Rennes, France